OptimizeRx (NASDAQ:OPRX) Now Covered by Analysts at Stephens

Analysts at Stephens assumed coverage on shares of OptimizeRx (NASDAQ:OPRX - Get Free Report) in a research report issued on Friday, MarketBeat.com reports. The brokerage set an "equal weight" rating and a $5.50 price target on the stock. Stephens' price objective would indicate a potential upside of 12.02% from the stock's current price.

A number of other research firms have also recently commented on OPRX. William Blair reissued an "outperform" rating on shares of OptimizeRx in a research note on Thursday, November 14th. Roth Mkm reiterated a "buy" rating and set a $16.00 price objective (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. JMP Securities decreased their target price on OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 14th. Barclays reduced their price objective on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating for the company in a research note on Thursday, November 14th. Finally, Stifel Nicolaus lowered their target price on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $9.71.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded up $0.16 during trading on Friday, reaching $4.91. 290,325 shares of the company's stock traded hands, compared to its average volume of 162,423. The firm has a market cap of $90.45 million, a PE ratio of -3.69 and a beta of 1.34. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a 50-day simple moving average of $5.41 and a 200-day simple moving average of $7.87.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares of the company's stock, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently modified their holdings of the business. Barclays PLC raised its stake in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after acquiring an additional 21,060 shares during the period. Bullseye Asset Management LLC increased its holdings in OptimizeRx by 55.6% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company's stock valued at $1,652,000 after purchasing an additional 76,458 shares during the last quarter. BNP Paribas Financial Markets raised its position in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock valued at $28,000 after purchasing an additional 2,414 shares during the period. Quest Partners LLC lifted its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after purchasing an additional 9,739 shares in the last quarter. Finally, Greenwood Capital Associates LLC boosted its position in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company's stock worth $520,000 after buying an additional 4,999 shares during the period. Institutional investors and hedge funds own 76.47% of the company's stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.